Health Sciences University Sureyyapasa Chest Diseases and Chest Surgery Hospital Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial
2020
NCT04446637
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Health Sciences University Sureyyapasa Chest Diseases and Chest Surgery Hospital | Istanbul Sureyyapasa Chest Diseases and Chest Surgery Training and Research Hospital | sureyyapasa chest diseases and chest surgery hospital | Sureyyapasa Training and Research Center for Chest Diseases and Thoracic Surgery, Maltepe, Istanbul - Turkey

Active Ingredients

Drugs in Phase 3 Trials (3)

albuterol (proventil) (1 trial)

ipratropium (atrovent) (1 trial)

levalbuterol (xopenex) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Lung Diseases (Phase 3)

Lung Diseases, Obstructive (Phase 3)

Pulmonary Disease, Chronic Obstructive (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 3